“Use of the 40-Gene Expression Profile (40-GEP) Test in Medicare-Eligible Patients Diagnosed with Cutaneous Squamous Cell Carcinoma (cSCC) to Guide Adjuvant Radiation Therapy (ART) Decisions Leads to a Significant Reduction in Healthcare Costs ”, J of Skin, vol. 8, no. 1, p. s336, Jan. 2024, doi: 10.25251/skin.8.supp.336.